Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary
Immunocore reported a 1.4% YoY revenue decline to $102.22M in Q3 2026, with a widened net loss of $14.22M. U.S. sales fell due to stocking adjustments and fewer sales weeks, partially offset by European and international growth. R&D spending increased, impacting results. KIMMTRAK is approved in 39 countries, and TEBE-AM Phase 3 trial enrollment is complete, with data expected in Q2 2027.
How this was made
The 30-second read
Why it matters
The earnings miss could trigger a sell‑off, but ongoing trial milestones may provide upside catalysts.
Market read
Small‑cap biotech earnings miss with widening loss; potential short‑term downside for IMCR.
What to watch
Positive European sales growth and pipeline progress may offset short‑term earnings weakness.
Background
Immunocore Holdings plc filed its 10‑Q for Q3 2026, reporting a modest revenue decline and a sharply larger net loss.
Ticker impact
Q3 2026 results show revenue down 1.4% YoY and net loss widening to $14.2M.
downward pressure as investors price in weaker revenue and larger loss.
Revenue decline and a 79x increase in net loss are material negative surprises for a small‑cap biotech.
Market effects
Biotech sector may see slight pullback as a peer reports weaker earnings.
UK‑listed biotech could face broader investor caution.
Limited to niche biotech investors.
Counterpoint
If the market overreacts to the loss, a bounce could occur on upcoming trial data.
Key entities
- companyImmunocore Holdings plc
UK‑based biotech developing T‑cell receptor therapies.